CLYM-116

N/A

Report date: 2026/04/28 20:00:22

Base Information

Drug NameCLYM-116
Drug Alias NameCLYM116MIL116
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionTumor necrosis factor ligand superfamily member 13 modulators
TargetsTumor necrosis factor ligand superfamily member 13
Therapy Area/IndicationsGlomerulonephritis, IGA
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesBeijing Mabworks Biotech Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBeijing Huafang Tianshi Biopharmaceutical Co LtdEliem Therapeutics IncBeijing Mabworks Biotech Co Ltd
Inactive CompaniesN/A
Active IndicationsGlomerulonephritis, IGA
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A